Related Experiment Videos
Ongoing US cooperative group trials using taxanes in the adjuvant setting
1Johns Hopkins Oncology Center, Baltimore, MD 21231-1000, USA. davidna@jhmi.edu
Clinical Breast Cancer
|November 19, 2002
Summary
Systemic adjuvant therapy, including taxanes like paclitaxel and docetaxel, significantly impacts survival for early-stage breast cancer patients. Ongoing research aims to solidify the role of these taxanes in adjuvant chemotherapy regimens.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Systemic adjuvant therapy is crucial for improving survival in early-stage breast cancer.
- Paclitaxel and docetaxel show high activity in advanced breast cancer and can be combined with anthracyclines.
Purpose of the Study:
- To evaluate the role of paclitaxel and docetaxel in adjuvant chemotherapy for early-stage breast cancer.
- To assess the impact of taxane-based regimens on patient survival and recurrence risk.
Main Methods:
- Review of randomized trials investigating taxanes (paclitaxel, docetaxel) in the adjuvant setting.
- Analysis of key trials such as Cancer and Leukemia Group B 9344 and Breast Cancer International Research Group 001.
Main Results:
- The Cancer and Leukemia Group B 9344 trial indicated a 22% reduction in relapse risk and 26% in death risk with paclitaxel addition.
- The Breast Cancer International Research Group 001 trial showed a 32% reduction in recurrence risk with a docetaxel-containing regimen.
Conclusions:
- Taxanes show promise in adjuvant therapy for early-stage breast cancer, potentially improving outcomes.
- Further trials are necessary to definitively establish the role and optimal use of taxanes in adjuvant breast cancer treatment.